Clin2
NCT03351855Possibly a fitTerminated

HPV immune cells (CTLs) for HPV treatment

Human Papilloma Virus

Part of Infections clinical trials.

This trial tests whether specially grown immune cells (HPV-CTLs) can fight HPV by targeting the virus. It is for people whose HPV infection has not responded to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
100 people
Ages
6 months to 75 years
Study type
Interventional

Who can take part

  • You have an active HPV infection confirmed by DNA test or biopsy.
  • You have tried standard treatments or they are not right for you.
  • You are under 75 years old.
  • You are not taking penicillin or strong antibiotics.
  • Your blood cell counts and liver/kidney function are within safe ranges.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05582590Not yet recruiting· Phase 1
T-cell therapy for HPV throat cancer after prior treatments

This early-phase study tests a lab-made treatment using your own immune cells (T cells) to target HPV-related throat cancers. It aims to reduce cancer by directing your immune system against HPV16/HPV18 and a protein called survivin.

NCT05639972Recruiting· Phase 1/Phase 2
HPV cancer trial using immune T cells made for you

This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.

New Brunswick, New Jersey
NCT06505551Not yet recruiting· Phase 1/Phase 2
Modified immune cells for HPV-related advanced cancers

This trial tests a new treatment using your own immune cells (called T cells) that are modified to target HPV-positive cancer cells. It may be an option if you have advanced cervical, head/neck, anal, penile, vulvar, or vaginal cancer that is HPV16 or HPV52 positive and has progressed after standard therapy.

NCT05686226Recruiting· Phase 2
Trial tests immune cells targeting HPV-16 cancers

This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.

Bethesda, Maryland
NCT06544720Recruiting· Phase 1
SCG142 TCR-T cell therapy for HPV-related cancers

This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.

Qingdao, Shandong
NCT07513324Not yet recruiting· Phase 2
Blood test guided therapy for HPV throat cancer

This trial tests whether a blood test measuring HPV DNA can help doctors decide the best treatment for HPV-positive throat cancer. The goal is to use this information to guide whether patients need immunotherapy (a drug called pembrolizumab) after their initial treatment.

Boston, Massachusetts

Hear when a new Human Papilloma Virus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.